A sight into the pathogenesis and treatment of thyroid-associated ophthalmopathy

Skrócona strona pozycji
dc.contributor.authorKrzemienowska-Cebulla, Aleksandra
dc.contributor.authorPuziewicz-Krzemienowska, Małgorzata
dc.contributor.authorDorochowicz, Mateusz
dc.contributor.authorMatus, Iwona
dc.date.accessioned2024-06-19T19:02:51Z
dc.date.available2024-06-19T19:02:51Z
dc.date.issued2024-06
dc.description.abstractIntroduction and aim. Thyroid-associated ophthalmopathy (TAO), often referred to as thyroid eye disease or Graves’ ophthalmopathy, is a syndrome characterized by autoimmune inflammation affecting the eye muscles, connective tissue, and orbital fat. The aim of this literature review is to present TAO and integrate the available data in the literature regarding the pathogenesis and treatment methods. Based on these, the authors aim to examine whether, despite the extensive knowledge already available on TAO, there are still issues to be investigated. Material and methods. In this literature review, books and scientific publications in both Polish and English languages have been assessed. The search criteria included keywords such as TAO, Graves’ disease, thyroid-associated ophthalmopathy. The evaluation covered the following databases: PubMed, Scopus, Google Scholar. Analysis of the literature. Typically, the eyeball is not involved, but in exceptional cases, corneal ulceration may occur, or inflammation of the optic nerve may ensue. TAO most commonly occurs in the course of hyperthyroidism in Graves’ disease, involving up to 25–50% of cases. The coexistence of autoantigens shared between the thyroid and orbital tissues is considered the primary cause of TAO when it occurs concurrently with hyperthyroidism, later in its course, or even preceding the manifestation of hyperthyroidism, with or without concurrent thyroid dysfunction. TAO is generally bilateral, although dominance on one side is often observed. Common symptoms include eye pain, photophobia, diplopia, varying degrees of proptosis, and impaired vision. The cornerstone of treatment lies in managing hyperthyroidism, as TAO cannot be cured without it. Conclusion. First-line treatment involves glucocorticoids, with radiation therapy as a supplementary option, and in cases unresponsive to pharmacological treatment, surgical intervention may be necessary.eng
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 22, z. 2 (2024), s. 432-438
dc.identifier.doi10.15584/ejcem.2024.2.28
dc.identifier.eissn2544-1361
dc.identifier.urihttps://repozytorium.ur.edu.pl/handle/item/10617
dc.language.isoeng
dc.publisherPublishing Office of the University of Rzeszow
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Poland*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/pl/*
dc.subjectGraves’ disease
dc.subjectTAO
dc.subjectthyroid-associated ophthalmopathy
dc.subjectthyroid eye disease
dc.titleA sight into the pathogenesis and treatment of thyroid-associated ophthalmopathy
dc.typearticle
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
24.a_sight_into_the_pathogenesis_and_treatment_of_thyroid-associated_ophthalmopathy_0.pdf
Rozmiar:
203.56 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.28 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.22, z. 2 (2024)